In yesterday’s Wall Street session, Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) shares traded at $9.61, down -6.79% from the previous session.
As of this writing, 3 analysts cover Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $9.00, we find $15.00. Given the previous closing price of $10.31, this indicates a potential upside of 45.49 percent. IRWD stock price is now -10.97% away from the 50-day moving average and -13.39% away from the 200-day moving average. The market capitalization of the company currently stands at $1.48B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 1 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $14.67 as their price target over the next twelve months.
With the price target of $15, CapitalOne recently initiated with Overweight rating for Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD).
In other news, MCCOURT Thomas A, Chief Executive Officer sold 26,632 shares of the company’s stock on May 30. The stock was sold for $284,962 at an average price of $10.70. Upon completion of the transaction, the Chief Executive Officer now directly owns 758,284 shares in the company, valued at $7.29 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 22, Chief Executive Officer MCCOURT Thomas A sold 36,000 shares of the business’s stock. A total of $364,320 was realized by selling the stock at an average price of $10.12. This leaves the insider owning 784,916 shares of the company worth $7.54 million. Insiders disposed of 585,510 shares of company stock worth roughly $5.63 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IRWD stock. A new stake in Ironwood Pharmaceuticals Inc. shares was purchased by BALYASNY ASSET MANAGEMENT L.P. during the first quarter worth $9,137,000. BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC invested $4,883,000 in shares of IRWD during the first quarter. In the first quarter, TWINBEECH CAPITAL LP acquired a new stake in Ironwood Pharmaceuticals Inc. valued at approximately $1,921,000. ALPHACENTRIC ADVISORS LLC acquired a new stake in IRWD for approximately $1,514,000. SQUAREPOINT OPS LLC purchased a new stake in IRWD valued at around $1,469,000 in the second quarter. In total, there are 361 active investors with 105.26% ownership of the company’s stock.
Wednesday morning saw Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) opened at $10.31. During the past 12 months, Ironwood Pharmaceuticals Inc. has had a low of $9.73 and a high of $12.66. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 36.30, and a quick ratio of 36.30. The fifty day moving average price for IRWD is $10.77 and a two-hundred day moving average price translates $11.09 for the stock.
The latest earnings results from Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.31, beating analysts’ expectations of $0.25 by 0.06. This compares to $0.20 EPS in the same period last year. The net profit margin was 43.60% and return on equity was 29.30% for IRWD. The company reported revenue of $104.06 million for the quarter, compared to $97.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.7 percent. For the current quarter, analysts expect IRWD to generate $112.99M in revenue.
